Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin + Lenalidomide in Relapsed/Refractory Lymphomas and Myeloma
NCT01755975Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2012
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of romidepsin in B cell lymphoma, T-cell lymphoma, Hodgkin lymphoma (HL), multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2012; status: completed.
02
Drugs
romidepsin
03
Conditions
B cell lymphomaT-cell lymphomaHodgkin lymphoma (HL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01755975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01755975.